Liminatus Pharma Stock (NASDAQ:LIMN)

Ownership Financials Chart

Previous Close

$0.16

52W Range

$0.13 - $33.66

50D Avg

$0.20

200D Avg

$1.03

Market Cap

$4.83M

Avg Vol (3M)

$9.92M

Beta

0.76

Div Yield

-

LIMN Company Profile

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

May 01, 2025

Website

LIMN Performance

LIMN Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-2.97M	$-2.91M	$-2.59M
Net Income	$-10.21M	$-2.90M	$-1.23M
EBITDA	$-2.97M	$-2.75M	$-1.09M
Basic EPS	$-0.43	$-0.40	$-0.15
Diluted EPS	$-0.43	$-0.40	$-0.15

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DYAI	Dyadic International, Inc.
EVAX	Evaxion Biotech A/S
MURA	Mural Oncology plc
JSPR	Jasper Therapeutics, Inc.
BTAI	BioXcel Therapeutics, Inc.
SABS	SAB Biotherapeutics, Inc.
GBIO	Generation Bio Co.
ATHE	Alterity Therapeutics Limited